$97.9 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$140.85 - $249.27The lowest and highst price in the last 52 weeks.
49.41xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$1.00 (0.48%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$97.9 Billion|
|Enterprise Value||$101 Billion|
|Dividend Yield||$1.00 (0.48%)|
|1 Year Return||+28.8%|
|Outstanding Shares||473 Million|
|Avg 30 Day Volume||2.05 Million|
|Earnings per Share||$4.15|
|Price to Sales Ratio||12.67|
|Price to Book Ratio||22.52|
|Revenue to Enterprise Value||13.3|
|EBIT to Enterprise Value||37.06|
|Total Debt to Enterprise Value||0.07|
|Debt to Equity||1.41|
|Gross Profit||$5.31 Billion|
|Net Income||$1.98 Billion|
|Quarterly Earnings Growth (YoY)||+15.2%|
|Return on Equity||42.36%|
|Return on Assets||14.46%|
|Return on Invested Capital||22.33%|
20,521 shares sold (2 transactions)
8,342 shares sold (3 transactions)
17,130 shares sold (4 transactions)
CEO: Kristin Peck
Industry: Pharmaceutical Preparation Manufacturing
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
HTF MI Analyst have added a new research study on Title Worldwide Pet Pharmaceuticals Market In-depth Research Report 2021, Forecast to 2026 with detailed in...OpenPR, about 2 months ago
Related Stocks: ZTS ,GuruFocus, about 2 months ago
Zoetis Inc. found using ticker (ZTS) have now 13 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 240 a...DirectorsTalk, about 2 months ago
Lantz Financial LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 13.7% in the 3rd quarter, Holdings Channel reports. The firm owned 1,283 shar...Transcript Daily, about 2 months ago